Global Peptide Cancer Vaccine Market Growth 2022-2028
As the global economy mends, the 2021 growth of Peptide Cancer Vaccine will have significant change from previous year. According to our latest study, the global Peptide Cancer Vaccine market size is USD million in 2022 from USD 535 million in 2021, with a change of % between 2021 and 2022. The global Peptide Cancer Vaccine market size will reach USD 1978.2 million in 2028, growing at a CAGR of 20.5% over the analysis period.
The United States Peptide Cancer Vaccine market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Peptide Cancer Vaccine market, reaching US$ million by the year 2028. As for the Europe Peptide Cancer Vaccine landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Peptide Cancer Vaccine players cover Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, and TapImmune, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Peptide Cancer Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by pipeline: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
ITK-1
GRN-1201
TPIV200
TPIV110
UV1
Galinpepimut-S
TARP 27-35
HER-Vaxx
Vx-001
Others
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Breast Cancer
Lung Cancer
Melanoma
Prostate Cancer
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Boston Biomedical
Ultimovacs
BrightPath Biotherapeutics
TapImmune
Immatics
Sellas
Imugene
VAXON Biotech
Generex Biotechnology
ISA Pharmaceuticals
OncoTherapy Science
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Peptide Cancer Vaccine Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Peptide Cancer Vaccine by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Peptide Cancer Vaccine by Country/Region, 2017, 2022 & 2028
2.2 Peptide Cancer Vaccine Segment by Pipeline
2.2.1 ITK-1
2.2.2 GRN-1201
2.2.3 TPIV200
2.2.4 TPIV110
2.2.5 UV1
2.2.6 Galinpepimut-S
2.2.7 TARP 27-35
2.2.8 HER-Vaxx
2.2.9 Vx-001
2.2.10 Others
2.3 Peptide Cancer Vaccine Sales by Pipeline
2.3.1 Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2017-2022)
2.3.2 Global Peptide Cancer Vaccine Revenue and Market Share by Pipeline (2017-2022)
2.3.3 Global Peptide Cancer Vaccine Sale Price by Pipeline (2017-2022)
2.4 Peptide Cancer Vaccine Segment by Application
2.4.1 Breast Cancer
2.4.2 Lung Cancer
2.4.3 Melanoma
2.4.4 Prostate Cancer
2.4.5 Others
2.5 Peptide Cancer Vaccine Sales by Application
2.5.1 Global Peptide Cancer Vaccine Sale Market Share by Application (2017-2022)
2.5.2 Global Peptide Cancer Vaccine Revenue and Market Share by Application (2017-2022)
2.5.3 Global Peptide Cancer Vaccine Sale Price by Application (2017-2022)
3 Global Peptide Cancer Vaccine by Company
3.1 Global Peptide Cancer Vaccine Breakdown Data by Company
3.1.1 Global Peptide Cancer Vaccine Annual Sales by Company (2020-2022)
3.1.2 Global Peptide Cancer Vaccine Sales Market Share by Company (2020-2022)
3.2 Global Peptide Cancer Vaccine Annual Revenue by Company (2020-2022)
3.2.1 Global Peptide Cancer Vaccine Revenue by Company (2020-2022)
3.2.2 Global Peptide Cancer Vaccine Revenue Market Share by Company (2020-2022)
3.3 Global Peptide Cancer Vaccine Sale Price by Company
3.4 Key Manufacturers Peptide Cancer Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Peptide Cancer Vaccine Product Location Distribution
3.4.2 Players Peptide Cancer Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Peptide Cancer Vaccine by Geographic Region
4.1 World Historic Peptide Cancer Vaccine Market Size by Geographic Region (2017-2022)
4.1.1 Global Peptide Cancer Vaccine Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Peptide Cancer Vaccine Annual Revenue by Geographic Region
4.2 World Historic Peptide Cancer Vaccine Market Size by Country/Region (2017-2022)
4.2.1 Global Peptide Cancer Vaccine Annual Sales by Country/Region (2017-2022)
4.2.2 Global Peptide Cancer Vaccine Annual Revenue by Country/Region
4.3 Americas Peptide Cancer Vaccine Sales Growth
4.4 APAC Peptide Cancer Vaccine Sales Growth
4.5 Europe Peptide Cancer Vaccine Sales Growth
4.6 Middle East & Africa Peptide Cancer Vaccine Sales Growth
5 Americas
5.1 Americas Peptide Cancer Vaccine Sales by Country
5.1.1 Americas Peptide Cancer Vaccine Sales by Country (2017-2022)
5.1.2 Americas Peptide Cancer Vaccine Revenue by Country (2017-2022)
5.2 Americas Peptide Cancer Vaccine Sales by Pipeline
5.3 Americas Peptide Cancer Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Peptide Cancer Vaccine Sales by Region
6.1.1 APAC Peptide Cancer Vaccine Sales by Region (2017-2022)
6.1.2 APAC Peptide Cancer Vaccine Revenue by Region (2017-2022)
6.2 APAC Peptide Cancer Vaccine Sales by Pipeline
6.3 APAC Peptide Cancer Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Peptide Cancer Vaccine by Country
7.1.1 Europe Peptide Cancer Vaccine Sales by Country (2017-2022)
7.1.2 Europe Peptide Cancer Vaccine Revenue by Country (2017-2022)
7.2 Europe Peptide Cancer Vaccine Sales by Pipeline
7.3 Europe Peptide Cancer Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Peptide Cancer Vaccine by Country
8.1.1 Middle East & Africa Peptide Cancer Vaccine Sales by Country (2017-2022)
8.1.2 Middle East & Africa Peptide Cancer Vaccine Revenue by Country (2017-2022)
8.2 Middle East & Africa Peptide Cancer Vaccine Sales by Pipeline
8.3 Middle East & Africa Peptide Cancer Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Peptide Cancer Vaccine
10.3 Manufacturing Process Analysis of Peptide Cancer Vaccine
10.4 Industry Chain Structure of Peptide Cancer Vaccine
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Peptide Cancer Vaccine Distributors
11.3 Peptide Cancer Vaccine Customer
12 World Forecast Review for Peptide Cancer Vaccine by Geographic Region
12.1 Global Peptide Cancer Vaccine Market Size Forecast by Region
12.1.1 Global Peptide Cancer Vaccine Forecast by Region (2023-2028)
12.1.2 Global Peptide Cancer Vaccine Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Peptide Cancer Vaccine Forecast by Pipeline
12.7 Global Peptide Cancer Vaccine Forecast by Application
13 Key Players Analysis
13.1 Boston Biomedical
13.1.1 Boston Biomedical Company Information
13.1.2 Boston Biomedical Peptide Cancer Vaccine Product Offered
13.1.3 Boston Biomedical Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Boston Biomedical Main Business Overview
13.1.5 Boston Biomedical Latest Developments
13.2 Ultimovacs
13.2.1 Ultimovacs Company Information
13.2.2 Ultimovacs Peptide Cancer Vaccine Product Offered
13.2.3 Ultimovacs Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Ultimovacs Main Business Overview
13.2.5 Ultimovacs Latest Developments
13.3 BrightPath Biotherapeutics
13.3.1 BrightPath Biotherapeutics Company Information
13.3.2 BrightPath Biotherapeutics Peptide Cancer Vaccine Product Offered
13.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 BrightPath Biotherapeutics Main Business Overview
13.3.5 BrightPath Biotherapeutics Latest Developments
13.4 TapImmune
13.4.1 TapImmune Company Information
13.4.2 TapImmune Peptide Cancer Vaccine Product Offered
13.4.3 TapImmune Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 TapImmune Main Business Overview
13.4.5 TapImmune Latest Developments
13.5 Immatics
13.5.1 Immatics Company Information
13.5.2 Immatics Peptide Cancer Vaccine Product Offered
13.5.3 Immatics Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Immatics Main Business Overview
13.5.5 Immatics Latest Developments
13.6 Sellas
13.6.1 Sellas Company Information
13.6.2 Sellas Peptide Cancer Vaccine Product Offered
13.6.3 Sellas Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Sellas Main Business Overview
13.6.5 Sellas Latest Developments
13.7 Imugene
13.7.1 Imugene Company Information
13.7.2 Imugene Peptide Cancer Vaccine Product Offered
13.7.3 Imugene Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Imugene Main Business Overview
13.7.5 Imugene Latest Developments
13.8 VAXON Biotech
13.8.1 VAXON Biotech Company Information
13.8.2 VAXON Biotech Peptide Cancer Vaccine Product Offered
13.8.3 VAXON Biotech Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 VAXON Biotech Main Business Overview
13.8.5 VAXON Biotech Latest Developments
13.9 Generex Biotechnology
13.9.1 Generex Biotechnology Company Information
13.9.2 Generex Biotechnology Peptide Cancer Vaccine Product Offered
13.9.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Generex Biotechnology Main Business Overview
13.9.5 Generex Biotechnology Latest Developments
13.10 ISA Pharmaceuticals
13.10.1 ISA Pharmaceuticals Company Information
13.10.2 ISA Pharmaceuticals Peptide Cancer Vaccine Product Offered
13.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 ISA Pharmaceuticals Main Business Overview
13.10.5 ISA Pharmaceuticals Latest Developments
13.11 OncoTherapy Science
13.11.1 OncoTherapy Science Company Information
13.11.2 OncoTherapy Science Peptide Cancer Vaccine Product Offered
13.11.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 OncoTherapy Science Main Business Overview
13.11.5 OncoTherapy Science Latest Developments
14 Research Findings and Conclusion
List of Tables
Table 1. Peptide Cancer Vaccine Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Peptide Cancer Vaccine Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of ITK-1
Table 4. Major Players of GRN-1201
Table 5. Major Players of TPIV200
Table 6. Major Players of TPIV110
Table 7. Major Players of UV1
Table 8. Major Players of Galinpepimut-S
Table 9. Major Players of TARP 27-35
Table 10. Major Players of HER-Vaxx
Table 11. Major Players of Vx-001
Table 12. Major Players of Others
Table 13. Global Peptide Cancer Vaccine Sales by Pipeline (2017-2022) & (K Doses)
Table 14. Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2017-2022)
Table 15. Global Peptide Cancer Vaccine Revenue by Pipeline (2017-2022) & ($ million)
Table 16. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2017-2022)
Table 17. Global Peptide Cancer Vaccine Sale Price by Pipeline (2017-2022) & (USD/Dose)
Table 18. Global Peptide Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
Table 19. Global Peptide Cancer Vaccine Sales Market Share by Application (2017-2022)
Table 20. Global Peptide Cancer Vaccine Revenue by Application (2017-2022)
Table 21. Global Peptide Cancer Vaccine Revenue Market Share by Application (2017-2022)
Table 22. Global Peptide Cancer Vaccine Sale Price by Application (2017-2022) & (USD/Dose)
Table 23. Global Peptide Cancer Vaccine Sales by Company (2020-2022) & (K Doses)
Table 24. Global Peptide Cancer Vaccine Sales Market Share by Company (2020-2022)
Table 25. Global Peptide Cancer Vaccine Revenue by Company (2020-2022) ($ Millions)
Table 26. Global Peptide Cancer Vaccine Revenue Market Share by Company (2020-2022)
Table 27. Global Peptide Cancer Vaccine Sale Price by Company (2020-2022) & (USD/Dose)
Table 28. Key Manufacturers Peptide Cancer Vaccine Producing Area Distribution and Sales Area
Table 29. Players Peptide Cancer Vaccine Products Offered
Table 30. Peptide Cancer Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 31. New Products and Potential Entrants
Table 32. Mergers & Acquisitions, Expansion
Table 33. Global Peptide Cancer Vaccine Sales by Geographic Region (2017-2022) & (K Doses)
Table 34. Global Peptide Cancer Vaccine Sales Market Share Geographic Region (2017-2022)
Table 35. Global Peptide Cancer Vaccine Revenue by Geographic Region (2017-2022) & ($ millions)
Table 36. Global Peptide Cancer Vaccine Revenue Market Share by Geographic Region (2017-2022)
Table 37. Global Peptide Cancer Vaccine Sales by Country/Region (2017-2022) & (K Doses)
Table 38. Global Peptide Cancer Vaccine Sales Market Share by Country/Region (2017-2022)
Table 39. Global Peptide Cancer Vaccine Revenue by Country/Region (2017-2022) & ($ millions)
Table 40. Global Peptide Cancer Vaccine Revenue Market Share by Country/Region (2017-2022)
Table 41. Americas Peptide Cancer Vaccine Sales by Country (2017-2022) & (K Doses)
Table 42. Americas Peptide Cancer Vaccine Sales Market Share by Country (2017-2022)
Table 43. Americas Peptide Cancer Vaccine Revenue by Country (2017-2022) & ($ Millions)
Table 44. Americas Peptide Cancer Vaccine Revenue Market Share by Country (2017-2022)
Table 45. Americas Peptide Cancer Vaccine Sales by Type (2017-2022) & (K Doses)
Table 46. Americas Peptide Cancer Vaccine Sales Market Share by Pipeline (2017-2022)
Table 47. Americas Peptide Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
Table 48. Americas Peptide Cancer Vaccine Sales Market Share by Application (2017-2022)
Table 49. APAC Peptide Cancer Vaccine Sales by Region (2017-2022) & (K Doses)
Table 50. APAC Peptide Cancer Vaccine Sales Market Share by Region (2017-2022)
Table 51. APAC Peptide Cancer Vaccine Revenue by Region (2017-2022) & ($ Millions)
Table 52. APAC Peptide Cancer Vaccine Revenue Market Share by Region (2017-2022)
Table 53. APAC Peptide Cancer Vaccine Sales by Pipeline (2017-2022) & (K Doses)
Table 54. APAC Peptide Cancer Vaccine Sales Market Share by Pipeline (2017-2022)
Table 55. APAC Peptide Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
Table 56. APAC Peptide Cancer Vaccine Sales Market Share by Application (2017-2022)
Table 57. Europe Peptide Cancer Vaccine Sales by Country (2017-2022) & (K Doses)
Table 58. Europe Peptide Cancer Vaccine Sales Market Share by Country (2017-2022)
Table 59. Europe Peptide Cancer Vaccine Revenue by Country (2017-2022) & ($ Millions)
Table 60. Europe Peptide Cancer Vaccine Revenue Market Share by Country (2017-2022)
Table 61. Europe Peptide Cancer Vaccine Sales by Type (2017-2022) & (K Doses)
Table 62. Europe Peptide Cancer Vaccine Sales Market Share by Pipeline (2017-2022)
Table 63. Europe Peptide Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
Table 64. Europe Peptide Cancer Vaccine Sales Market Share by Application (2017-2022)
Table 65. Middle East & Africa Peptide Cancer Vaccine Sales by Country (2017-2022) & (K Doses)
Table 66. Middle East & Africa Peptide Cancer Vaccine Sales Market Share by Country (2017-2022)
Table 67. Middle East & Africa Peptide Cancer Vaccine Revenue by Country (2017-2022) & ($ Millions)
Table 68. Middle East & Africa Peptide Cancer Vaccine Revenue Market Share by Country (2017-2022)
Table 69. Middle East & Africa Peptide Cancer Vaccine Sales by Pipeline (2017-2022) & (K Doses)
Table 70. Middle East & Africa Peptide Cancer Vaccine Sales Market Share by Pipeline (2017-2022)
Table 71. Middle East & Africa Peptide Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
Table 72. Middle East & Africa Peptide Cancer Vaccine Sales Market Share by Application (2017-2022)
Table 73. Key Market Drivers & Growth Opportunities of Peptide Cancer Vaccine
Table 74. Key Market Challenges & Risks of Peptide Cancer Vaccine
Table 75. Key Industry Trends of Peptide Cancer Vaccine
Table 76. Peptide Cancer Vaccine Raw Material
Table 77. Key Suppliers of Raw Materials
Table 78. Peptide Cancer Vaccine Distributors List
Table 79. Peptide Cancer Vaccine Customer List
Table 80. Global Peptide Cancer Vaccine Sales Forecast by Region (2023-2028) & (K Doses)
Table 81. Global Peptide Cancer Vaccine Sales Market Forecast by Region
Table 82. Global Peptide Cancer Vaccine Revenue Forecast by Region (2023-2028) & ($ millions)
Table 83. Global Peptide Cancer Vaccine Revenue Market Share Forecast by Region (2023-2028)
Table 84. Americas Peptide Cancer Vaccine Sales Forecast by Country (2023-2028) & (K Doses)
Table 85. Americas Peptide Cancer Vaccine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 86. APAC Peptide Cancer Vaccine Sales Forecast by Region (2023-2028) & (K Doses)
Table 87. APAC Peptide Cancer Vaccine Revenue Forecast by Region (2023-2028) & ($ millions)
Table 88. Europe Peptide Cancer Vaccine Sales Forecast by Country (2023-2028) & (K Doses)
Table 89. Europe Peptide Cancer Vaccine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 90. Middle East & Africa Peptide Cancer Vaccine Sales Forecast by Country (2023-2028) & (K Doses)
Table 91. Middle East & Africa Peptide Cancer Vaccine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 92. Global Peptide Cancer Vaccine Sales Forecast by Pipeline (2023-2028) & (K Doses)
Table 93. Global Peptide Cancer Vaccine Sales Market Share Forecast by Pipeline (2023-2028)
Table 94. Global Peptide Cancer Vaccine Revenue Forecast by Pipeline (2023-2028) & ($ Millions)
Table 95. Global Peptide Cancer Vaccine Revenue Market Share Forecast by Pipeline (2023-2028)
Table 96. Global Peptide Cancer Vaccine Sales Forecast by Application (2023-2028) & (K Doses)
Table 97. Global Peptide Cancer Vaccine Sales Market Share Forecast by Application (2023-2028)
Table 98. Global Peptide Cancer Vaccine Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 99. Global Peptide Cancer Vaccine Revenue Market Share Forecast by Application (2023-2028)
Table 100. Boston Biomedical Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 101. Boston Biomedical Peptide Cancer Vaccine Product Offered
Table 102. Boston Biomedical Peptide Cancer Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 103. Boston Biomedical Main Business
Table 104. Boston Biomedical Latest Developments
Table 105. Ultimovacs Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 106. Ultimovacs Peptide Cancer Vaccine Product Offered
Table 107. Ultimovacs Peptide Cancer Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 108. Ultimovacs Main Business
Table 109. Ultimovacs Latest Developments
Table 110. BrightPath Biotherapeutics Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 111. BrightPath Biotherapeutics Peptide Cancer Vaccine Product Offered
Table 112. BrightPath Biotherapeutics Peptide Cancer Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 113. BrightPath Biotherapeutics Main Business
Table 114. BrightPath Biotherapeutics Latest Developments
Table 115. TapImmune Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 116. TapImmune Peptide Cancer Vaccine Product Offered
Table 117. TapImmune Peptide Cancer Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 118. TapImmune Main Business
Table 119. TapImmune Latest Developments
Table 120. Immatics Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 121. Immatics Peptide Cancer Vaccine Product Offered
Table 122. Immatics Peptide Cancer Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 123. Immatics Main Business
Table 124. Immatics Latest Developments
Table 125. Sellas Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 126. Sellas Peptide Cancer Vaccine Product Offered
Table 127. Sellas Peptide Cancer Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 128. Sellas Main Business
Table 129. Sellas Latest Developments
Table 130. Imugene Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 131. Imugene Peptide Cancer Vaccine Product Offered
Table 132. Imugene Peptide Cancer Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 133. Imugene Main Business
Table 134. Imugene Latest Developments
Table 135. VAXON Biotech Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 136. VAXON Biotech Peptide Cancer Vaccine Product Offered
Table 137. VAXON Biotech Peptide Cancer Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 138. VAXON Biotech Main Business
Table 139. VAXON Biotech Latest Developments
Table 140. Generex Biotechnology Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 141. Generex Biotechnology Peptide Cancer Vaccine Product Offered
Table 142. Generex Biotechnology Peptide Cancer Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 143. Generex Biotechnology Main Business
Table 144. Generex Biotechnology Latest Developments
Table 145. ISA Pharmaceuticals Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 146. ISA Pharmaceuticals Peptide Cancer Vaccine Product Offered
Table 147. ISA Pharmaceuticals Peptide Cancer Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 148. ISA Pharmaceuticals Main Business
Table 149. ISA Pharmaceuticals Latest Developments
Table 150. OncoTherapy Science Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 151. OncoTherapy Science Peptide Cancer Vaccine Product Offered
Table 152. OncoTherapy Science Peptide Cancer Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 153. OncoTherapy Science Main Business
Table 154. OncoTherapy Science Latest Developments
List of Figures
Figure 1. Picture of Peptide Cancer Vaccine
Figure 2. Peptide Cancer Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Peptide Cancer Vaccine Sales Growth Rate 2017-2028 (K Doses)
Figure 7. Global Peptide Cancer Vaccine Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Peptide Cancer Vaccine Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of ITK-1
Figure 10. Product Picture of GRN-1201
Figure 11. Product Picture of TPIV200
Figure 12. Product Picture of TPIV110
Figure 13. Product Picture of UV1
Figure 14. Product Picture of Galinpepimut-S
Figure 15. Product Picture of TARP 27-35
Figure 16. Product Picture of HER-Vaxx
Figure 17. Product Picture of Vx-001
Figure 18. Product Picture of Others
Figure 19. Global Peptide Cancer Vaccine Sales Market Share by Pipeline in 2021
Figure 20. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2017-2022)
Figure 21. Peptide Cancer Vaccine Consumed in Breast Cancer
Figure 22. Global Peptide Cancer Vaccine Market: Breast Cancer (2017-2022) & (K Doses)
Figure 23. Peptide Cancer Vaccine Consumed in Lung Cancer
Figure 24. Global Peptide Cancer Vaccine Market: Lung Cancer (2017-2022) & (K Doses)
Figure 25. Peptide Cancer Vaccine Consumed in Melanoma
Figure 26. Global Peptide Cancer Vaccine Market: Melanoma (2017-2022) & (K Doses)
Figure 27. Peptide Cancer Vaccine Consumed in Prostate Cancer
Figure 28. Global Peptide Cancer Vaccine Market: Prostate Cancer (2017-2022) & (K Doses)
Figure 29. Peptide Cancer Vaccine Consumed in Others
Figure 30. Global Peptide Cancer Vaccine Market: Others (2017-2022) & (K Doses)
Figure 31. Global Peptide Cancer Vaccine Sales Market Share by Application (2017-2022)
Figure 32. Global Peptide Cancer Vaccine Revenue Market Share by Application in 2021
Figure 33. Peptide Cancer Vaccine Revenue Market by Company in 2021 ($ Million)
Figure 34. Global Peptide Cancer Vaccine Revenue Market Share by Company in 2021
Figure 35. Global Peptide Cancer Vaccine Sales Market Share by Geographic Region (2017-2022)
Figure 36. Global Peptide Cancer Vaccine Revenue Market Share by Geographic Region in 2021
Figure 37. Global Peptide Cancer Vaccine Sales Market Share by Region (2017-2022)
Figure 38. Global Peptide Cancer Vaccine Revenue Market Share by Country/Region in 2021
Figure 39. Americas Peptide Cancer Vaccine Sales 2017-2022 (K Doses)
Figure 40. Americas Peptide Cancer Vaccine Revenue 2017-2022 ($ Millions)
Figure 41. APAC Peptide Cancer Vaccine Sales 2017-2022 (K Doses)
Figure 42. APAC Peptide Cancer Vaccine Revenue 2017-2022 ($ Millions)
Figure 43. Europe Peptide Cancer Vaccine Sales 2017-2022 (K Doses)
Figure 44. Europe Peptide Cancer Vaccine Revenue 2017-2022 ($ Millions)
Figure 45. Middle East & Africa Peptide Cancer Vaccine Sales 2017-2022 (K Doses)
Figure 46. Middle East & Africa Peptide Cancer Vaccine Revenue 2017-2022 ($ Millions)
Figure 47. Americas Peptide Cancer Vaccine Sales Market Share by Country in 2021
Figure 48. Americas Peptide Cancer Vaccine Revenue Market Share by Country in 2021
Figure 49. United States Peptide Cancer Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 50. Canada Peptide Cancer Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 51. Mexico Peptide Cancer Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 52. Brazil Peptide Cancer Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 53. APAC Peptide Cancer Vaccine Sales Market Share by Region in 2021
Figure 54. APAC Peptide Cancer Vaccine Revenue Market Share by Regions in 2021
Figure 55. China Peptide Cancer Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 56. Japan Peptide Cancer Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 57. South Korea Peptide Cancer Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 58. Southeast Asia Peptide Cancer Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 59. India Peptide Cancer Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 60. Australia Peptide Cancer Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 61. Europe Peptide Cancer Vaccine Sales Market Share by Country in 2021
Figure 62. Europe Peptide Cancer Vaccine Revenue Market Share by Country in 2021
Figure 63. Germany Peptide Cancer Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 64. France Peptide Cancer Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 65. UK Peptide Cancer Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 66. Italy Peptide Cancer Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 67. Russia Peptide Cancer Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 68. Middle East & Africa Peptide Cancer Vaccine Sales Market Share by Country in 2021
Figure 69. Middle East & Africa Peptide Cancer Vaccine Revenue Market Share by Country in 2021
Figure 70. Egypt Peptide Cancer Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 71. South Africa Peptide Cancer Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 72. Israel Peptide Cancer Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 73. Turkey Peptide Cancer Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 74. GCC Country Peptide Cancer Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 75. Manufacturing Cost Structure Analysis of Peptide Cancer Vaccine in 2021
Figure 76. Manufacturing Process Analysis of Peptide Cancer Vaccine
Figure 77. Industry Chain Structure of Peptide Cancer Vaccine
Figure 78. Channels of Distribution
Figure 79. Distributors Profiles
